Login to Your Account



ROI continues to decline for top pharma firms, according to Deloitte survey

By Nuala Moran
Staff Writer

Wednesday, January 3, 2018

LONDON – As the row over drug pricing gets louder, the return on investment (ROI) among the top 12 pharma companies continues to slide, according to the latest annual survey carried out by consultants at Deloitte LLP.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription